Everest Medicines Limited (HKG:1952)

Market Cap	10.60B -45.4%
Revenue (ttm)	2.78B +182.9%
Net Income	-62.25M
EPS	-0.20
Shares Out	351.58M
PE Ratio	n/a
Forward PE	18.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,333,734
Open	28.02
Previous Close	27.98
Day's Range	28.02 - 30.48
52-Week Range	22.70 - 58.60
Beta	1.56
Analysts	Buy
Price Target	40.65 (+34.87%)
Est. Earnings	Nov 20, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 812
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1952

Financial Performance

In 2025, Everest Medicines's revenue was 1.71 billion, an increase of 141.51% compared to the previous year's 706.68 million. Losses were -297.77 million, -71.41% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 6 analysts, the average rating for 1952 stock is "Buy." The 12-month stock price target is $40.65, which is an increase of 34.87% from the latest price.

Price Target

$40.65

(34.87% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error